ResMed Inc. Announces Results for the First Quarter of Fiscal Year 2022

Rhea-AI Summary

ResMed reported a 20% increase in revenue to $904.0 million for Q1 fiscal 2022, with operating profit up 21%. Non-GAAP operating profit rose 18%, and diluted EPS reached $1.39. Despite COVID-19 related demand fluctuations impacting ventilator sales, the growth was fueled by strong demand for sleep and respiratory products, alongside a recent competitor recall. However, gross margins contracted due to rising costs. The company settled a significant tax dispute, impacting cash flow but providing clarity for future operations.

Positive

• Revenue increased by 20% year-over-year.
• Operating profit climbed by 21%.
• Non-GAAP diluted EPS rose by 19%.
• Strong demand for sleep and respiratory care products.

Negative

• Gross margin decreased by 270 bps to 57.2%.
• Operating cash flow was negative $65.7 million, influenced by a tax settlement.

• Year-over-year revenue grows 20%, operating profit up 21%, non-GAAP operating profit up 18%

Note: A webcast of ResMed’s conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com

SAN DIEGO, Oct. 28, 2021 (GLOBE NEWSWIRE) -- ResMed Inc. (NYSE: RMD, ASX: RMD), a world-leading digital health company, today announced results for its quarter ended September 30, 2021.

First Quarter 2022 Highlights
All comparisons are to the prior year period

• Revenue increased by 20% to $904.0 million; up 19% on a constant currency basis
• Gross margin of 56.0%; non-GAAP gross margin contracted 270 bps to 57.2%
• Income from operations increased 21%; non-GAAP operating profit up 18%
• Diluted earnings per share of $1.39; non-GAAP diluted earnings per share of $1.51

“Our first-quarter results demonstrate strong performance across our business with double-digit growth in both top-line and bottom-line metrics, driven by ongoing high demand for our sleep and respiratory care products, and steady growth across our software-as-a-service business,” said Mick Farrell, ResMed CEO. “It is through the extraordinary efforts of our global ResMed team that we were able to deliver products and solutions to our customers amid unprecedented supply chain challenges that continue to restrict access to critical electronic components. As we navigate supply limitations and are forced to allocate products, we continue to ensure priority for highest-acuity and highest-need patients first, as well as working with physicians, providers, and community systems to maintain a sustainable flow of medical devices and digital health solutions to patients who need care.”

“Despite constantly evolving market dynamics, we continue to pivot to meet the needs of our stakeholders, driving sustainable long-term growth, and ensuring that we are investing strongly in medical device research and development, as well as digital health innovation that will unlock value for all of our customers. I’m incredibly proud of our global teams that are working with providers and physicians in the most unusual times across 140 countries, to get products directly into the hands of patients who need our solutions most.”

Financial Results and Operating Metrics
Unaudited; $ in millions, except for per share amounts

	Three Months Ended
	September 30, 2021				September 30, 2020				% Change			Constant Currency (A)
Revenue	$	904.0			$	751.9			20	%		19	%
Gross margin (B)		56.0	%			58.3	%		(4	)
Non-GAAP gross margin (B)		57.2	%			59.9	%		(5	)
Selling, general, and administrative expenses		176.7				159.0			11			10
Research and development expenses		60.0				54.5			10			9
Income from operations		261.9				216.9			21
Non-GAAP income from operations (B)		280.7				237.1			18
Net income		203.6				178.4			14
Non-GAAP net income (B)		222.0				185.4			20
Diluted earnings per share	$	1.39			$	1.22			14
Non-GAAP diluted earnings per share (B)	$	1.51			$	1.27			19

(A)

In order to provide a framework for assessing how our underlying businesses performed excluding the effect of foreign currency fluctuations, we provide certain financial information on a “constant currency” basis, which is in addition to the actual financial information presented. In order to calculate our constant currency information, we translate the current period financial information using the foreign currency exchange rates that were in effect during the previous comparable period. However, constant currency measures should not be considered in isolation or as an alternative to U.S. dollar measures that reflect current period exchange rates, or to other financial measures calculated and presented in accordance with U.S. GAAP.

(B)

See the reconciliation of non-GAAP financial measures in the table at the end of the press release.

Discussion of First Quarter Results
All comparisons are to the prior year period unless otherwise noted

• Revenue grew by 19% on a constant currency basis, driven by increased demand for our sleep and respiratory care devices and increased demand following a recent product recall by one of our competitors, partially offset by decreased COVID-19 related demand for ventilators.
  • The current quarter did not include material incremental respiratory care revenue from COVID-19 related demand whereas the prior year quarter included incremental revenue of approximately $40.0 million. Excluding the impact of incremental respiratory care revenue associated with COVID-19 in the prior year quarter, revenue increased by 25 percent on a constant currency basis.
  • Revenue in the U.S., Canada, and Latin America, excluding Software as a Service, grew by 22 percent, primarily due to the factors discussed above and recovery of core sleep patient flow that was previously impacted by COVID-19. Excluding the prior year impact of incremental respiratory care revenue associated with COVID-19, revenue increased by 28 percent.
  • Revenue in Europe, Asia, and other markets grew by 21 percent on a constant currency basis, primarily due to the factors discussed above and strong sales across our mask product portfolio. Excluding the prior year impact of incremental respiratory care revenue associated with COVID-19, revenue increased by 29 percent on a constant currency basis.
  • Software as a Service revenue increased by 6 percent, due to continued growth in resupply service offerings and stabilizing patient flow in out-of-hospital care settings.
• Gross margin decreased by 230 basis points and non-GAAP gross margin decreased by 270 basis points, mainly due to higher manufacturing costs, incremental freight costs, and lower average selling prices.
• Selling, general, and administrative expenses increased by 10 percent on a constant currency basis. SG&A expenses improved to 19.5 percent of revenue in the quarter, compared with 21.1 percent in the same period of the prior year. These changes in SG&A expenses were mainly due to increases in employee-related expenses.
• Income from operations increased by 21 percent and non-GAAP income from operations increased by 18 percent.
• Net income grew by 14 percent and diluted earnings per share grew by 14 percent. Non-GAAP net income grew by 20 percent and non-GAAP diluted earnings per share grew by 19 percent, predominantly attributable to strong sales.
• Operating cash flow for the quarter was negative $65.7 million and was impacted by a payment to the Australian Tax Office of $284.8 million, which was the settlement amount of $381.7 million net of prior remittances. After adjusting for this payment, our operating cash flow for the quarter was $219.1 million, compared to net income in the current quarter of $203.6 million and non-GAAP net income of $222.0 million. During the quarter we paid $61.2 million in dividends.

Other Business and Operational Highlights

• Introduced the AirSense 11 in the U.S., ResMed’s next-generation PAP (positive airway pressure) device designed to help millions of people worldwide with sleep apnea start and stay on therapy to treat and manage obstructive sleep apnea.
• Announced the promotion of Bobby Ghoshal to President of ResMed’s SaaS business.
• Presented new research at the European Respiratory Society (ERS) International Congress 2021 including the landmark ALASKA study, “CPAP Termination and All-Cause Mortality: a French Nationwide Database Analysis,” that concludes people with obstructive sleep apnea who continue PAP therapy are 39% more likely to survive than OSA patients who don’t.
• During the quarter, concluded the settlement agreement with the Australian Taxation Office (“ATO”), which fully resolves the transfer pricing dispute for all prior years since 2009. ResMed previously recognized a tax reserve in fiscal year 2021 in anticipation of the settlement.
  • The net impact of the settlement was $238.7 million ($381.7 million gross less credits and deductions of $143.0 million). The settlement provides closure for historic Australian tax matters and greater clarity into the future.
  • As a result of the ATO settlement and due to movements in foreign currencies, recognized a $4.1 million reduction in tax credits during the quarter, which was recorded as an increase in income tax expense.

Dividend program
The ResMed board of directors today declared a quarterly cash dividend of $0.42 per share. The dividend will have a record date of November 11, 2021, payable on December 16, 2021. The dividend will be paid in U.S. currency to holders of ResMed’s common stock trading on the New York Stock Exchange. Holders of CHESS Depositary Interests (“CDIs”) trading on the Australian Securities Exchange will receive an equivalent amount in Australian currency, based on the exchange rate on the record date, and reflecting the 10:1 ratio between CDIs and NYSE shares. The ex-dividend date will be November 10, 2021, for common stockholders and for CDI holders. ResMed has received a waiver from the ASX’s settlement operating rules, which will allow ResMed to defer processing conversions between its common stock and CDI registers from November 10, 2021, through November 11, 2021, inclusive.

Webcast details
ResMed will discuss its first quarter fiscal year 2022 results on its webcast at 1:30 p.m. U.S. Pacific Time today. The live webcast of the call can be accessed on ResMed’s Investor Relations website at investor.resmed.com. Please go to this section of the website and click on the icon for the “Q1 2022 Earnings Webcast” to register and listen to the live webcast. A replay of the earnings webcast will be accessible on the website and available approximately two hours after the live webcast. In addition, a telephone replay of the conference call will be available approximately two hours after the webcast by dialing +1 877-660-6853 (U.S.) or +1 201-612-7415 (outside U.S.) and entering the passcode 13723324. The telephone replay will be available until November 11, 2021.

About ResMed
At ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, we improve quality of life, reduce the impact of chronic disease, and lower costs for consumers and healthcare systems in more than 140 countries. To learn more, visit ResMed.com and follow @ResMed.

Safe harbor statement
Statements contained in this release that are not historical facts are “forward-looking” statements as contemplated by the Private Securities Litigation Reform Act of 1995. These forward-looking statements – including statements regarding ResMed’s projections of future revenue or earnings, expenses, new product development, new product launches, new markets for its products, the integration of acquisitions, litigation, and tax outlook – are subject to risks and uncertainties, which could cause actual results to materially differ from those projected or implied in the forward-looking statements. Additional risks and uncertainties are discussed in ResMed’s periodic reports on file with the U.S. Securities & Exchange Commission. ResMed does not undertake to update its forward-looking statements.

RESMED INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Operations
(Unaudited; $ in thousands, except for per share amounts)

	Three Months Ended
	September 30, 2021				September 30, 2020
Net revenue	$	904,015			$	751,944
Cost of sales		386,667				301,304
Amortization of acquired intangibles (1)		11,059				11,979
Restructuring - cost of sales (1)		-				-
Total cost of sales	$	397,726			$	313,283
Gross profit	$	506,289			$	438,661
Selling, general, and administrative		176,719				158,989
Research and development		59,950				54,533
Amortization of acquired intangibles (1)		7,707				8,243
Total operating expenses	$	244,376			$	221,765
Income from operations		261,913				216,896
Other income (expenses), net:
Interest income (expense), net	$	(5,360	)		$	(6,725	)
Loss attributable to equity method investments		(1,386	)			(2,288	)
Other, net		3,621				7,971
Total other income (expenses), net		(3,125	)			(1,042	)
Income before income taxes	$	258,788			$	215,854
Income taxes		55,175				37,482
Net income	$	203,613			$	178,372
Basic earnings per share	$	1.40			$	1.23
Diluted earnings per share	$	1.39			$	1.22
Non-GAAP diluted earnings per share (1)	$	1.51			$	1.27
Basic shares outstanding		145,680				144,900
Diluted shares outstanding		146,860				146,100

(1)	See the reconciliation of non-GAAP financial measures in the table at the end of the press release.

RESMED INC. AND SUBSIDIARIES

Condensed Consolidated Balance Sheets
(Unaudited; $ in thousands)

	September 30, 2021				June 30, 2021
ASSETS
Current assets:
Cash and cash equivalents	$	276,149			$	295,278
Accounts receivable, net		575,554				614,292
Inventories		506,644				457,033
Prepayments and other current assets		227,908				208,154
Total current assets	$	1,586,255			$	1,574,757
Non-current assets:
Property, plant and equipment, net	$	467,344			$	463,490
Operating lease right-of-use assets		134,375				128,575
Goodwill and other intangibles, net		2,297,437				2,320,483
Deferred income taxes and other non-current assets		243,756				240,820
Total non-current assets	$	3,142,912			$	3,153,368
Total assets	$	4,729,167			$	4,728,125
LIABILITIES AND STOCKHOLDERS’ EQUITY:
Current liabilities:
Accounts payable	$	173,696			$	138,008
Accrued expenses		274,106				320,599
Operating lease liabilities, current		22,919				23,585
Deferred revenue		112,528				109,611
Income taxes payable		28,909				307,963
Short-term debt		12,000				12,000
Total current liabilities	$	624,158			$	911,766
Non-current liabilities:
Deferred revenue	$	93,255			$	91,496
Deferred income taxes		11,294				11,319
Operating lease liabilities, non-current		121,518				114,779
Other long-term liabilities		5,981				6,802
Long-term debt		793,668				643,351
Long-term income taxes payable		53,244				62,933
Total non-current liabilities	$	1,078,960			$	930,680
Total liabilities	$	1,703,118			$	1,842,446
STOCKHOLDERS’ EQUITY:
Common stock	$	583			$	583
Additional paid-in capital		1,643,661				1,622,199
Retained earnings		3,222,064				3,079,640
Treasury stock		(1,623,256	)			(1,623,256	)
Accumulated other comprehensive income		(217,003	)			(193,487	)
Total stockholders’ equity	$	3,026,049			$	2,885,679
Total liabilities and stockholders' equity	$	4,729,167			$	4,728,125

RESMED INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Cash Flows
(Unaudited; $ in thousands)

	Three Months Ended
	September 30, 2021				September 30, 2020
Cash flows from operating activities:
Net income	$	203,613			$	178,372
Adjustment to reconcile net income to cash provided by operating activities:
Depreciation and amortization		39,102				39,466
Amortization of right-of-use assets		8,517				10,422
Stock-based compensation costs		17,303				16,071
Loss attributable to equity method investments		1,386				2,288
(Gain) loss on equity investment		(5,612	)			(8,476	)
Changes in operating assets and liabilities:
Accounts receivable, net		33,704				16,110
Inventories, net		(55,976	)			(52,396	)
Prepaid expenses, net deferred income taxes, and other current assets		(14,391	)			3,415
Accounts payable, accrued expenses, income taxes payable, and other		(293,303	)			(61,273	)
Net cash (used in) / provided by operating activities	$	(65,657	)		$	143,999
Cash flows from investing activities:
Purchases of property, plant, and equipment		(27,340	)			(13,501	)
Patent registration and acquisition costs		(4,453	)			(5,237	)
Purchases of investments		(6,600	)			(8,196	)
(Payments) / proceeds on maturity of foreign currency contracts		(3,481	)			4,824
Net cash used in investing activities	$	(41,874	)		$	(22,110	)
Cash flows from financing activities:
Proceeds from issuance of common stock, net		4,354				1,026
Taxes paid related to net share settlement of equity awards		(195	)			227
Proceeds from borrowings, net of borrowing costs		150,000				55,000
Repayment of borrowings		-				(175,000	)
Dividends paid		(61,189	)			(56,511	)
Net cash (used in) / provided by financing activities	$	92,970			$	(175,258	)
Effect of exchange rate changes on cash	$	(4,568	)		$	11,627
Net increase / (decrease) in cash and cash equivalents		(19,129	)			(41,742	)
Cash and cash equivalents at beginning of period		295,278				463,156
Cash and cash equivalents at end of period	$	276,149			$	421,414

RESMED INC. AND SUBSIDIARIES

Reconciliation of Non-GAAP Financial Measures
(Unaudited; $ in thousands, except for per share amounts)

The measures “non-GAAP gross profit” and “non-GAAP gross margin” exclude amortization expense from acquired intangibles related to cost of sales and are reconciled below:

	Three Months Ended
	September 30, 2021				September 30, 2020
Revenue	$	904,015			$	751,944
GAAP cost of sales	$	397,726			$	313,283
Less: Amortization of acquired intangibles (A)		(11,059	)			(11,979	)
Non-GAAP cost of sales	$	386,667			$	301,304
GAAP gross profit	$	506,289			$	438,661
GAAP gross margin		56.0	%			58.3	%
Non-GAAP gross profit	$	517,348			$	450,640
Non-GAAP gross margin		57.2	%			59.9	%

The measure “non-GAAP income from operations” is reconciled with GAAP income from operations below:

	Three Months Ended
	September 30, 2021				September 30, 2020
GAAP income from operations	$	261,913			$	216,896
Amortization of acquired intangibles - cost of sales (A)		11,059				11,979
Amortization of acquired intangibles - operating expenses (A)		7,707				8,243
Non-GAAP income from operations	$	280,679			$	237,118

RESMED INC. AND SUBSIDIARIES

Reconciliation of Non-GAAP Financial Measures
(Unaudited; $ in thousands, except for per share amounts)

The measures “non-GAAP net income” and “non-GAAP diluted earnings per share” are reconciled with GAAP net income and GAAP diluted earnings per share in the table below:

	Three Months Ended
	September 30, 2021				September 30, 2020
GAAP net income	$	203,613			$	178,372
Amortization of acquired intangibles - cost of sales, net of tax (A)		8,435				9,169
Amortization of acquired intangibles - operating expenses, net of tax (A)		5,878				6,309
Reserve for disputed tax position (A)		4,111				-
(Gain) loss on equity investments (A)		-				(8,476	)
Non-GAAP net income (A)	$	222,037			$	185,374
GAAP diluted shares outstanding		146,860				146,100
GAAP diluted earnings per share	$	1.39			$	1.22
Non-GAAP diluted earnings per share (A)	$	1.51			$	1.27

(A)	ResMed adjusts for the impact of the amortization of acquired intangibles, reserve for disputed tax positions, and the (gain) loss on equity investments from their evaluation of ongoing operations and believes that investors benefit from adjusting these items to facilitate a more meaningful evaluation of current operating performance.
	ResMed believes that non-GAAP diluted earnings per share is an additional measure of performance that investors can use to compare operating results between reporting periods. ResMed uses non-GAAP information internally in planning, forecasting, and evaluating the results of operations in the current period and in comparing it to past periods. ResMed believes this information provides investors better insight when evaluating ResMed’s performance from core operations and provides consistent financial reporting. The use of non-GAAP measures is intended to supplement, and not to replace, the presentation of net income and other GAAP measures. Like all non-GAAP measures, non-GAAP earnings are subject to inherent limitations because they do not include all the expenses that must be included under GAAP.

RESMED INC. AND SUBSIDIARIES

Revenue by Product and Region
(Unaudited; $ in millions, except for per share amounts)

	Three Months Ended
	September 30, 2021 (A)			September 30, 2020 (A)			% Change			Constant Currency (B)
U.S., Canada, and Latin America
Devices	$	275.9		$	197.4		40	%
Masks and other		215.1			205.8		5
Total Sleep and Respiratory Care	$	491.0		$	403.2		22
Software as a Service		97.5			92.1		6
Total	$	588.6		$	495.3		19
Combined Europe, Asia, and other markets
Devices	$	218.2		$	176.0		24	%		22	%
Masks and other		97.2			80.6		21			18
Total Sleep and Respiratory Care	$	315.5		$	256.6		23			21
Global revenue
Devices	$	494.2		$	373.4		32	%		31	%
Masks and other		312.3			286.4		9			8
Total Sleep and Respiratory Care	$	806.5		$	659.8		22			21
Software as a Service		97.5			92.1		6			6
Total	$	904.0		$	751.9		20			19

(A)

Totals and subtotals may not add due to rounding.

(B)

In order to provide a framework for assessing how our underlying businesses performed excluding the effect of foreign currency fluctuations, we provide certain financial information on a “constant currency basis,” which is in addition to the actual financial information presented. In order to calculate our constant currency information, we translate the current period financial information using the foreign currency exchange rates that were in effect during the previous comparable period. However, constant currency measures should not be considered in isolation or as an alternative to U.S. dollar measures that reflect current period exchange rates, or to other financial measures calculated and presented in accordance with U.S. GAAP.

For investors	For media
Amy Wakeham	Jayme Rubenstein
+1 858-836-5000	+1 858-836-6798
investorrelations@resmed.com	news@resmed.com

FAQ

What were ResMed's revenue figures for Q1 fiscal 2022?

ResMed reported revenues of $904.0 million for Q1 fiscal 2022, a 20% increase year-over-year.

How did ResMed's net income change in Q1 fiscal 2022?

Net income for Q1 fiscal 2022 grew by 14% to $203.6 million.

What is the diluted EPS for ResMed in Q1 fiscal 2022?

Diluted earnings per share for Q1 fiscal 2022 were $1.39, a 14% increase from the previous year.

What impact did COVID-19 have on ResMed's sales?

Sales were partially offset by decreased demand for COVID-19 related ventilators, which had a material impact compared to the previous year.

What significant tax-related event occurred for ResMed in Q1 fiscal 2022?

ResMed concluded a settlement with the Australian Tax Office, impacting cash flow but providing resolution for historic tax matters.